Literature DB >> 33201799

The role of surgery in high risk and advanced prostate cancer: A narrative review.

Chloe Sheila Dayan Roy1, Ashwin Sachdeva1, Gokul Vignesh Kandaswamy2, Bhavan Prasad Rai1.   

Abstract

Patients with high-risk and advanced prostate cancer require safe and efficacious therapies likely to offer a survival advantage while minimizing the treatment-related toxicities. Improvements in the surgical technology, diagnostic modalities, radiological staging, and risk stratification have made surgery for high-risk and advanced prostate cancer a safe and feasible option. In this review, we outline the role of radical prostatectomy in high-risk localized, locally advanced, and metastatic prostate cancer. We overview available data evaluating the use of surgery in the context of a multi-modal approach and highlight ongoing trials in this area. Furthermore, the role of surgery as a non-systemic modality for metastasis-directed therapy (MDT) is also described. Emerging imaging modalities enabling more accurate staging and longer follow-up of clinical trials for prognostic endpoints are anticipated to help identify patient cohorts and treatment strategies, where the use of surgical treatments is likely to provide oncological benefits and acceptable toxicity.

Entities:  

Year:  2020        PMID: 33201799      PMCID: PMC8057352          DOI: 10.5152/tud.2020.20475

Source DB:  PubMed          Journal:  Turk J Urol        ISSN: 2149-3235


  44 in total

Review 1.  Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review.

Authors:  Guillaume Ploussard; Giorgio Gandaglia; Hendrik Borgmann; Pieter de Visschere; Isabel Heidegger; Alexander Kretschmer; Romain Mathieu; Cristian Surcel; Derya Tilki; Igor Tsaur; Massimo Valerio; Roderick van den Bergh; Piet Ost; Alberto Briganti
Journal:  Eur Urol       Date:  2018-10-31       Impact factor: 20.096

2.  Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.

Authors:  Axel Heidenreich; Nicola Fossati; David Pfister; Nazareno Suardi; Francesco Montorsi; Shahrokh Shariat; Bernhard Grubmüller; Giorgio Gandaglia; Alberto Briganti; R Jeffrey Karnes
Journal:  Eur Urol Oncol       Date:  2018-05-15

3.  SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer.

Authors:  J Stranne; K Brasso; B Brennhovd; E Johansson; F Jäderling; M Kouri; W Lilleby; P Meidahl Petersen; T Mirtti; A Pettersson; A Rannikko; C Thellenberg; O Akre
Journal:  Scand J Urol       Date:  2018-12-26       Impact factor: 1.612

4.  New prostate cancer grade grouping system predicts survival after radical prostatectomy.

Authors:  Andrew Erickson; Kevin Sandeman; Kanerva Lahdensuo; Stig Nordling; Markku Kallajoki; Heikki Seikkula; Anna Bützow; Hanna Vasarainen; Peter J Boström; Pekka Taimen; Antti Rannikko; Tuomas Mirtti
Journal:  Hum Pathol       Date:  2018-02-13       Impact factor: 3.466

Review 5.  Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease.

Authors:  Axel Heidenreich; David Pfister
Journal:  Curr Opin Urol       Date:  2020-01       Impact factor: 2.309

6.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

Authors:  Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford
Journal:  Eur Urol       Date:  2016-08-25       Impact factor: 20.096

Review 8.  The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.

Authors:  Bhavan Prasad Rai; Richard Paul Baum; Amit Patel; Robert Hughes; Roberto Alonzi; Tim Lane; Jim Adshead; Nikhil Vasdev
Journal:  Urology       Date:  2016-01-11       Impact factor: 2.649

9.  Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer.

Authors:  Malcolm D Mason; Wendy R Parulekar; Matthew R Sydes; Michael Brundage; Peter Kirkbride; Mary Gospodarowicz; Richard Cowan; Edmund C Kostashuk; John Anderson; Gregory Swanson; Mahesh K B Parmar; Charles Hayter; Gordana Jovic; Andrea Hiltz; John Hetherington; Jinka Sathya; James B P Barber; Michael McKenzie; Salah El-Sharkawi; Luis Souhami; P D John Hardman; Bingshu E Chen; Padraig Warde
Journal:  J Clin Oncol       Date:  2015-02-17       Impact factor: 44.544

10.  Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis.

Authors:  Nicola Fossati; Nazareno Suardi; Giorgio Gandaglia; Carlo A Bravi; Matteo Soligo; R Jeffrey Karnes; Shahrokh Shariat; Antonino Battaglia; Wouter Everaerts; Steven Joniau; Hendrik Van Poppel; Nieroshan Rajarubendra; Inderbir S Gill; Alessandro Larcher; Alexander Mottrie; Maximilian Schmautz; Axel Heidenreich; Almut Kalz; Daniar Osmonov; Klaus-Peter Juenemann; Annika Herlemann; Christian Gratzke; Christian Stief; Francesco Montorsi; Alberto Briganti
Journal:  Eur Urol       Date:  2018-10-06       Impact factor: 24.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.